Bromide

Bromide

SCHEMBL1331692

CCCCCCCCCCCCCCCCCCCC[n+]1ccccc1.[Br-]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 6/20 1.00
CHRM2 known ✓ P08172 2/20 1.00
CHRM1 known ✓ P11229 2/20 1.00
CHRM4 known ✓ P08173 1/20 1.00
CHRM5 known ✓ P08912 1/20 1.00
CHRM3 known ✓ P20309 1/20 1.00
OPRM1 known ✓ P35372 1/20 0.95
RAD52 P43351 3/20 1.00
HSP90AA1 P07900 2/20 1.00
ADRA2A P08913 2/20 1.00
ADORA3 P0DMS8 2/20 1.00
SLC6A2 P23975 2/20 1.00
SLC6A4 P31645 2/20 1.00
SLC6A3 Q01959 2/20 1.00
KMT2A Q03164 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
EGFR P00533 1/20 1.00
LMNA P02545 1/20 1.00
PLA2G1B P04054 1/20 1.00
ERBB2 P04626 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL8770083 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A
Bromide SCHEMBL557155 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A
Bromide SCHEMBL5286954 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A
Bromide SCHEMBL1547466 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A
Bromide SCHEMBL5085309 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A
Bromide SCHEMBL8650670 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A
Bromide SCHEMBL4540499 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A
Bromide SCHEMBL1331186 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A
Cetylpyridinium SCHEMBL151799 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A
Bromide SCHEMBL177665 1.00 ACHE (1.00) ACHERAD52HSP90AA1CHRM2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11549134-B2 Modified amadoriase and method for producing the same, agent for improving surfactant resistance of amadoriase and composition for measuring HbA1c using the same KIKKOMAN CORPORATION (JP) 2023-01-10 US claimed
US-20200263228-A1 MODIFIED AMADORIASE AND METHOD FOR PRODUCING THE SAME, AGENT FOR IMPROVING SURFACTANT RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING THE SAME KIKKOMAN CORPORATION (JP) 2020-08-20 US claimed
US-20160186232-A1 MODIFIED AMADORIASE AND METHOD FOR PRODUCING THE SAME, AGENT FOR IMPROVING SURFACTANT RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING THE SAME KIKKOMAN CORPORATION (JP) 2016-06-30 US claimed
EP-3031914-A1 MODIFIED AMADORIASE AND METHOD FOR PRODUCING SAME, AGENT FOR IMPROVING SURFACTANT-RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING SAME Kikkoman Corporation (JP) 2016-06-15 EP claimed
CN-105473715-A Modified amadoriase and method for producing same, surfactant resistance improver for amadoriase, and composition for measurement of HbA1c using same KIKKOMAN CORP 2016-04-06 CN claimed
CN-111398605-B Glycosylated hemoglobin measurement composition 龟甲万株式会社 2024-04-05 CN disclosed
EP-3279323-B1 AMADORIASE HAVING IMPROVED SPECIFIC ACTIVITY KIKKOMAN CORP (JP) 2023-03-08 EP disclosed
US-11549134-B2 Modified amadoriase and method for producing the same, agent for improving surfactant resistance of amadoriase and composition for measuring HbA1c using the same KIKKOMAN CORPORATION (JP) 2023-01-10 US disclosed
US-10934530-B2 Amadoriase having improved specific activity KIKKOMAN CORPORATION (JP) 2021-03-02 US disclosed
EP-3760717-A1 AMADORIASE AND METHOD FOR PRODUCING THE SAME, AGENT FOR IMPROVING SURFACTANT RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HBA1C USING THE SAME Kikkoman Corporation (JP) 2021-01-06 EP disclosed
EP-3031914-B1 MODIFIED AMADORIASE AND METHOD FOR PRODUCING THE SAME, AGENT FOR IMPROVING SURFACTANT RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HBA1C USING THE SAME KIKKOMAN CORP (JP) 2020-12-23 EP disclosed
US-20200263228-A1 MODIFIED AMADORIASE AND METHOD FOR PRODUCING THE SAME, AGENT FOR IMPROVING SURFACTANT RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING THE SAME KIKKOMAN CORPORATION (JP) 2020-08-20 US disclosed
US-20120264758-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO BYOCOAT ENTERPRISES, INC. (US) 2012-10-18 US disclosed
US-20110281002-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO BYOCOAT ENTERPRISES, INC. (PR) 2011-11-17 US disclosed
US-20090192165-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO BYOCOAT ENTERPRISES, INC. (PR) 2009-07-30 US disclosed
EP-1931209-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO Byocoat Enterprises, Inc. (US) 2008-06-18 EP disclosed
WO-2008008362-A2 COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING MICROORGANISM GROWTH OR SURVIVAL IN AQUEOUS ENVIRONMENTS BYOCOAT ENTERPRISES, INC. (US) 2008-01-17 WO disclosed
WO-2007030104-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO BYOCOAT ENTERPRISES, INC. (US) 2007-03-15 WO disclosed
US-20060110506-A1 Antimicrobial solutions and process related thereto BYOCOAT ENTERPRISES, INC. 2006-05-25 US disclosed
US-20050271781-A1 Antimicrobial solutions and process related thereto BYOCOAT ENTERPRISES, INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281002-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO DAO, AGPS, TH ACHE 1327/4885CHRM2 3847/4885CHRM1 3574/4885
US-20090192165-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO DAO, AGPS, DDC ACHE 2330/4885CHRM2 4551/4885CHRM1 4428/4885
US-20120264758-A1 ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO DAO, AGPS, DDC ACHE 2330/4885CHRM2 4551/4885CHRM1 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.